JP2017533945A5 - - Google Patents

Download PDF

Info

Publication number
JP2017533945A5
JP2017533945A5 JP2017526516A JP2017526516A JP2017533945A5 JP 2017533945 A5 JP2017533945 A5 JP 2017533945A5 JP 2017526516 A JP2017526516 A JP 2017526516A JP 2017526516 A JP2017526516 A JP 2017526516A JP 2017533945 A5 JP2017533945 A5 JP 2017533945A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
combination
sulbactam
combination according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017526516A
Other languages
English (en)
Japanese (ja)
Other versions
JP6764862B2 (ja
JP2017533945A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/061076 external-priority patent/WO2016081452A1/en
Publication of JP2017533945A publication Critical patent/JP2017533945A/ja
Publication of JP2017533945A5 publication Critical patent/JP2017533945A5/ja
Application granted granted Critical
Publication of JP6764862B2 publication Critical patent/JP6764862B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017526516A 2014-11-17 2015-11-17 耐性細菌感染症の治療のための併用療法 Active JP6764862B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462080667P 2014-11-17 2014-11-17
US62/080,667 2014-11-17
PCT/US2015/061076 WO2016081452A1 (en) 2014-11-17 2015-11-17 Combination therapy for treatment of resistant bacterial infections

Publications (3)

Publication Number Publication Date
JP2017533945A JP2017533945A (ja) 2017-11-16
JP2017533945A5 true JP2017533945A5 (OSRAM) 2018-12-20
JP6764862B2 JP6764862B2 (ja) 2020-10-07

Family

ID=54704148

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017526516A Active JP6764862B2 (ja) 2014-11-17 2015-11-17 耐性細菌感染症の治療のための併用療法

Country Status (31)

Country Link
US (2) US9968593B2 (OSRAM)
EP (1) EP3221313B1 (OSRAM)
JP (1) JP6764862B2 (OSRAM)
KR (1) KR102542392B1 (OSRAM)
CN (1) CN107108624B (OSRAM)
AU (1) AU2015350128B2 (OSRAM)
BR (1) BR112017010132B1 (OSRAM)
CA (1) CA2966632C (OSRAM)
CY (1) CY1121384T1 (OSRAM)
DK (1) DK3221313T3 (OSRAM)
EA (1) EA033829B1 (OSRAM)
ES (1) ES2717776T3 (OSRAM)
HK (1) HK1244798B (OSRAM)
HR (1) HRP20190580T1 (OSRAM)
HU (1) HUE044061T2 (OSRAM)
IL (1) IL251979B (OSRAM)
LT (1) LT3221313T (OSRAM)
ME (1) ME03357B (OSRAM)
MX (1) MX2017006383A (OSRAM)
MY (1) MY196240A (OSRAM)
PH (1) PH12017500852B1 (OSRAM)
PL (1) PL3221313T3 (OSRAM)
PT (1) PT3221313T (OSRAM)
RS (1) RS58429B1 (OSRAM)
SG (1) SG11201703633TA (OSRAM)
SI (1) SI3221313T1 (OSRAM)
SM (1) SMT201900187T1 (OSRAM)
TR (1) TR201905233T4 (OSRAM)
TW (1) TWI690317B (OSRAM)
WO (1) WO2016081452A1 (OSRAM)
ZA (1) ZA201703245B (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3221313T1 (sl) 2014-11-17 2019-04-30 Entasis Therapeutics Limited Kombinacijska terapija za zdravljenje okužb z rezistentnimi bakterijami
WO2017203266A1 (en) * 2016-05-25 2017-11-30 Entasis Therapeutics Limited Combination therapy for treatment of resistant bacterial infections
SMT202200397T1 (it) * 2016-09-16 2022-11-18 Entasis Therapeutics Ltd Composti inibitori di beta-lattamasi
EP3301094A1 (en) * 2016-09-30 2018-04-04 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
EA037916B1 (ru) * 2017-02-08 2021-06-07 Энтасис Терапеутикс Лимитед Соединения-ингибиторы бета-лактамаз
CN110709081B (zh) 2017-05-08 2023-09-22 恩塔西斯治疗公司 用于治疗细菌感染的化合物及方法
CN109422765B (zh) * 2017-09-05 2020-08-28 香港理工大学深圳研究院 C类β-内酰胺酶抑制剂及其制备方法和应用
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
EP3833665B1 (en) 2018-08-09 2023-07-19 Antabio SAS Diazabicyclooctanones as inhibitors of serine beta-lactamases
CN111658642A (zh) * 2019-03-05 2020-09-15 广州新创忆药物临床研究有限公司 一种治疗耐碳青霉烯类抗生素鲍曼不动杆菌感染的组合物
TWI715397B (zh) * 2019-12-31 2021-01-01 高雄榮民總醫院 根據領先標準將同儕數據繪製為圖表的方法、電腦程式產品及電腦可讀取媒體
EP4125905B1 (en) * 2020-04-02 2024-12-25 GlaxoSmithKline Intellectual Property Development Limited Regimen for treating a neisseria gonorrhoeae infection with gepotidacin
CN117062598A (zh) * 2021-01-20 2023-11-14 恩塔西斯治疗有限公司 固定剂量抗生素组合物
WO2023206580A1 (en) * 2022-04-29 2023-11-02 Entasis Therapeutics Limited Durlobactam crystalline forms

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ282567B6 (cs) 1993-12-29 1997-08-13 Pfizer Inc. Diazabicyklické sloučeniny a farmaceutické prostředky na jejich bázi
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2825705B1 (fr) * 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) * 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2848210B1 (fr) * 2002-12-06 2007-10-19 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
FR2914923B1 (fr) 2007-04-12 2013-06-14 Novexel Nouveaux composes heterocycliques azotes,leur preparation et leur utilisation comme medicaments antibacteriens.
SI2231667T1 (sl) * 2008-01-18 2013-12-31 Merck Sharp & Dohme Corp. Beta laktamazni inhibitorji
FR2930553B1 (fr) 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
EP3260551A1 (en) 2008-06-19 2017-12-27 Astra Zeneca Holding France Use of (1r,2s,5r) 1,6-diazabicyclo [3.2.1] octane-2-carboxamide, 7-oxo-6-(sulfooxy)-, monosodium salt as a diagnostic reagent for detecting serine beta-lactamases
FR2936798B1 (fr) 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
FR2937034B1 (fr) 2008-10-10 2012-11-23 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens
FR2936951B1 (fr) * 2008-10-10 2010-12-03 Novexel Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments
FR2951171A1 (fr) 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
RU2560846C1 (ru) 2011-07-26 2015-08-20 Вокхардт Лимитед Фармацевтические композиции, содержащие сулбактам и ингибитор бета-лактамазы
EP2768503A1 (en) * 2011-07-26 2014-08-27 Wockhardt Limited Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor
KR101512738B1 (ko) 2011-08-27 2015-04-17 욱크하르트 리미티드 1,6-디아자-비시클로[3,2,1]옥탄-7-온 유도체 및 세균 감염 치료에서의 그 유도체의 용도
JP5677634B2 (ja) 2011-08-30 2015-02-25 ウォックハート リミテッド 1,6−ジアザビシクロ[3,2,1]オクタン−7−オン誘導体および細菌感染の処置におけるそれらの使用
EP3052497B1 (en) 2011-09-13 2017-06-28 Wockhardt Limited Nitrogen containing compounds and their use
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
US20150119363A1 (en) * 2012-02-15 2015-04-30 Rempex Pharmaceuticals, Inc.. Methods of treating bacterial infections
SG11201406120SA (en) 2012-03-30 2014-10-30 Cubist Pharm Inc ISOXAZOLE β-LACTAMASE INHIBITORS
MX2014011827A (es) 2012-03-30 2015-02-20 Cubist Pharm Inc Inhibidores de 1,3,4 - oxadiazol y 1,3,4 - tiadiazol b-lactamasa.
US8916709B2 (en) 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
US8969570B2 (en) 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
AR090539A1 (es) 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
UA117734C2 (uk) 2012-05-30 2018-09-25 Мейдзі Сейка Фарма Ко., Лтд. НОВИЙ ІНГІБІТОР β-ЛАКТАМАЗИ І СПОСІБ ЙОГО ОДЕРЖАННЯ
BR112015003592B1 (pt) 2012-08-25 2020-04-14 Wockhardt Ltd derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e seu uso no tratamento de infecções bacterianas
US20150258072A1 (en) 2012-09-03 2015-09-17 Wockhardt Limited Antibacterial compositions
US20150374673A1 (en) * 2013-02-06 2015-12-31 Astrazeneca Ab Combination Therapy for the Treatment of Nosocomial Pneumonia
WO2014141132A1 (en) * 2013-03-14 2014-09-18 Naeja Pharmaceutical Inc. NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS
SI3221313T1 (sl) 2014-11-17 2019-04-30 Entasis Therapeutics Limited Kombinacijska terapija za zdravljenje okužb z rezistentnimi bakterijami

Similar Documents

Publication Publication Date Title
JP2017533945A5 (OSRAM)
PH12017500852B1 (en) Combination therapy for treatment of resistant bacterial infections
WO2018115527A3 (en) Mers coronavirus vaccine
MX2019009443A (es) Metodos para tratar la influenza.
NZ616806A (en) Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor
PH12016501577A1 (en) Monobactam organic compounds for the treatment of bacterial infections
UA107423C2 (en) Fluoro-pyridinone derivatives useful as antibacterial agents
EA201991523A1 (ru) Комбинированная терапия амидин-замещенными бета-лактамными соединениями и ингибиторами бета-лактамазы при инфекциях, вызванных бактериальными штаммами, резистентными к антибиотикам
CL2015002755A1 (es) Composiciones antibióticas de ceftolozano.
EA033446B1 (ru) Гетероциклическое соединение для лечения дегенерации желтого пятна и/или болезни штаргардта
ZA202002093B (en) Antibacterial compounds
WO2016086153A3 (en) Use of hsp90 inhibitors for the treatment of hiv infections and aids
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
SA517381678B1 (ar) مركبات داي هيدرو بيريميدين-2-أون واستخدامها الطبي
RU2017145271A (ru) Терапевтическое средство для фиброза
IN2014MU00916A (OSRAM)
WO2015130547A8 (en) Bis-cyclic guanidine compound compositions, methods of use and treatment thereof
EA201890653A1 (ru) Композиция с противовирусным эффектом
WO2015165964A8 (en) Treatment and prevention of alzheimer's disease (ad)
MX2017013433A (es) Composiciones antibacterianas.
PH12017502432A1 (en) Compositions and methods for using lamellar bodies for therapeutic purposes
AR110913A1 (es) Compuesto aminoglucósido y su uso para prevenir o tratar enfermedades infecciosas
EA201890122A1 (ru) Применение 2-(5s-метил-2-оксо-4r-фенилпирролидин-1-ил)ацетамида в лечении судорог
MX379489B (es) Metodos para tratar la osteocondromatosis multiple (mo).
PH12016501215A1 (en) Azaindole derivative